InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,470.80
(
0.30%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.52
(
0.47%
)
Bitcoin
64,645.84
(
1.01%
)
Post# of 251721
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oldberkeley post# 111391

Thursday, 12/23/2010 2:07:15 PM

Thursday, December 23, 2010 2:07:15 PM

Post# of 251721

“Teva will presumably try to turn the low-volume formulation into the centerpiece of its franchise defense.”

Basically, is that what's going on here?
That’s what was going on here, but the FDA just shot a hole in Teva’s plan.

Teva’s fallback position on defending the Copaxone franchise will now pass to the thrice-weekly 40mg formulation, which is being tested in a trial called GALA that is expected to report top-line data in late 2012 and the complete dataset in mid 2014 (#msg-57549803).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up